- Simultaneous development of pheochromocytomas in prepubertal siblings with von Hippel-Lindau syndrome.
- Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing.
- Early identification of patients with von Hippel-Lindau disease at risk for pheochromocytoma.
Table of Contents
1
UI - 12032534
AU - Franklin SL; Eisenhofer G; Geffner ME
TI -
Simultaneous development of pheochromocytomas in prepubertal siblings
with von Hippel-Lindau syndrome.
SO - J Pediatr 2002 May;140(5):625-8
AD - Division of Endocrinology, Department of Pediatrics, Mattel Children's
Hospital at UCLA, Los Angeles, California 90095, USA.
We report 2 siblings with a known von Hippel-Lindau mutation who
simultaneously developed asymptomatic pheochromocytomas at significantly
younger ages than are typically seen in this setting.
2
UI - 11865075
AU - Wiesener MS; Eckardt KU
TI -
Erythropoietin, tumours and the von Hippel-Lindau gene: towards
identification of mechanisms and dysfunction of oxygen sensing.
SO - Nephrol Dial Transplant 2002 Mar;17(3):356-9
3
UI - 12084291
AU - Maranchie JK; Walther MM
TI -
Early identification of patients with von Hippel-Lindau disease at risk
for pheochromocytoma.
SO - Curr Urol Rep 2001 Feb;2(1):24-30
AD - Urologic Oncology Branch, National Cancer Institute, 10101 Grosvenor
Place, #518, North Bethesda, MD 20852, USA. Maranchj@mail.nih.gov
von Hippel-Lindau disease (VHL) is an autosomal dominant familial
syndrome that predisposes to the formation of tumors in multiple organ
systems, including adrenal and extra-adrenal pheochromocytomas. However,
fewer than 30% of VHL families develop pheochromocytomas. In recent
years, this clinical heterogeneity has been correlated with missense
mutations. The VHL patient requires vigilant, lifelong biochemical and
radiographic screening for pheochromocytoma. Half of VHL
pheochromocytomas present bilaterally, and there is a high incidence of
recurrence after surgery. Because of the morbidity of bilateral total
adrenalectomy with subsequent steroid replacement therapy, the recent
therapeutic trend has been toward observation and minimally invasive
adrenal-sparing procedures.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home